Cardiovascular health, heart failure, atherosclerosis, and cardiac research
417 artigos
Um grande estudo com abordagem genômica revela lacunas críticas no diagnóstico de hipercolesterolemia familiar em pessoas de ancestralidade africana devido ao viés na classificação de variantes.
A comprehensive review reveals tirzepatide improves blood pressure, lipids, liver fat, kidney function, and slashes 10-year cardiovascular risk by up to 23.5%.
A novel CTSL–Notch1–CUX1 pathway drives endothelial senescence and atherosclerotic plaque buildup, revealing fresh drug targets.
A post hoc analysis of the CLEAR Outcomes trial finds bempedoic acid significantly reduces DVT and pulmonary embolism risk.
A new JAMA Cardiology analysis warns that rising temperatures and a growing elderly population are converging to produce an unprecedented cardiac emergency.
A completed registry study identified and genotyped HoFH patients with LDLR mutations, laying groundwork for targeted gene therapy.
Akeso's AK102 faces a placebo-controlled test in high-cardiovascular-risk patients already on statins and ezetimibe.
A completed Phase IIIb trial tests whether pelacarsen can safely lower Lp(a) in historically underrepresented cardiovascular disease populations.
A 3-month interval cycling program assessed cardiovascular and metabolic improvements in obese vs. normal-weight women.
Experts propose that structured anticoagulation services offer a blueprint for broader cardiovascular medication stewardship programs.
A formal correction is issued to the landmark 2025 multi-society hypertension guidelines, ensuring clinical accuracy for practitioners.
A correction to a landmark study linking breast cancer to latent BMPR2-driven pulmonary hypertension susceptibility in Circulation.
